The test uses multiplex PCR fragment analysis with Promega-designed five-mononucleotide repeat markers to detect the MSI-high phenotype within tumor tissues.
The two companies have signed a collaboration agreement to provide Promega's microsatellite instability testing technology for immuno-oncology.
Promega's technology will be part of a larger portfolio of research products aimed at supporting oncology drug and clinical trial development.
Promega would first seek clearance for an assay that detects dMMR in colorectal cancer patients, and could seek a far broader clearance in the long term.
The test, which is currently for research use only, uses fluorescent multiplex PCR to co-amplify seven markers for analysis of the MSI-high phenotype.